바이오어피니티 테크놀로지스BIAF 주가

bioAffinity Receives Mexican Institute Of Industrial Property Allowance For A Patent Application Regarding Methods Of Predicting The Likelihood Of Lung Cancer Using Flow Cytometry

Upon issuance, the Mexican patent application will protect the use of defined antibodies and the porphyrin TCPP to label cell populations in sputum and the use of flow cytometry to determine the presence of lung cancer

♻️ 재탕[8-K] 중대 사건 — 8-K

[S-8] S-8 — S-8

[424B3] 424B3 — 424B3

BioAffinity Technologies Reports April CyPath Lung Diagnostic Unit Sales Up 300% YoY

bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced that unit sales for its CyPath® Lung diagnostic test

bioAffinity Technologies Reports Record Monthly Unit Sales Of CyPath Lung Diagnostic Tests, 300% Increase In Sales YoY

bioAffinity Technologies has prioritized CyPath® Lung as its core commercial focus, aligning resources to accelerate adoption and scale. Growth has been driven by:Expansion of ordering physician sitesIncreased

BioAffinity Technologies Reports Record Monthly CyPath® Lung Unit Sales and Significant Year-Over-Year Growth in April 2026

CyPath® Lung unit sales in April increased nearly 300% compared to April 2025Increasing unit sales for CyPath® Lung continues first quarter 2026 trend of accelerating adoption and clinical...

[EFFECT] EFFECT

♻️ 재탕[8-K] 중대 사건 — 8-K

BioAffinity Technologies : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. This section presents management's perspective on our financial condition and results of...